Clinical trials: Mask
Dry Eye Disease
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
- Trial name
- NCT05629364
- Testing
- KIO-101
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Diabetic Macular Edema
A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.
This study will evaluate the efficacy of ultra low dose danazol (Optina™) for the treatment of diabetic macular edema.
- Trial name
- NCT01821677
- Testing
- Danazol Capsules
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Ampio Pharmaceuticals. Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 52 sites in United States, Argentina
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
X-Linked Retinitis Pigmentosa
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
- Trial name
- NCT06275620
- Testing
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beacon Therapeutics
Dry Eye Disease
Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)
The purpose of this pilot study is to evaluate the effect of diquafosol tetrasodium Ophthalmic Solution, 2% in dry eye subjects.
- Trial name
- NCT00600288
- Testing
- diquafosol tetrasodium Ophthalmic Solution, 2%
- Volunteers
- 261 people
- Sponsor
- Merck Sharp & Dohme LLC
Obstructive Sleep Apnea
Investigative Headgear With CPAP Mask
This investigation is designed to evaluate the at-home usability, performance, user acceptance and reliability of the Headgear with a CPAP Mask for a duration of 2-4 weeks.
- Trial name
- NCT02323035
- Testing
- Headgear
- Where
- New Zealand
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Fisher and Paykel Healthcare
Geographic Atrophy
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in…
- Trial name
- NCT02288559
- Testing
- Lampalizumab
- Where
- 36 sites in United States
- Volunteers
- 96 people
- Sponsor
- Genentech, Inc.
Adenoviral Conjunctivitis
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
- Trial name
- NCT02998541
- Testing
- SHP640, PVP-I 0.6%
- Where
- 130 sites in United States, Australia and 14 more
- Volunteers
- 219 people
- Sponsor
- Shire
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Dry Eye Syndrome
Study of ST266 Eye Drops in Treating Dry Eye
Subjects with moderate-to-severe Dry Eye by symptoms will be screened including history, ophthalmic examination to include the status of their ocular structure and function and evaluation of tear production.
- Trial name
- NCT02369861
- Testing
- ST266, Refresh Lubricant Eye Drops
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Glaucoma
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost.
- Trial name
- NCT01060579
- Testing
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Where
- 18 sites in United States
- Volunteers
- 217 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks.
- Trial name
- NCT00560638
- Testing
- loteprednol etabonate ophthalmic suspension, 0.5%, vehicle of loteprednol etabonate
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Bausch & Lomb Incorporated
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Obstructive Sleep Apnea
Investigative Headgear With Nasal Pillows Continuous Positive Airway Pressure (CPAP) Mask
This investigation is designed to evaluate the at-home usability, performance, user acceptance and reliability of the headgear with a CPAP mask for a duration of 6 months.
- Trial name
- NCT02942446
- Testing
- Investigative Headgear with CPAP mask
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Fisher and Paykel Healthcare
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Corneal Edema, Corneal Endothelial Dysfunction
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
- Trial name
- NCT07368959
- Testing
- Combination Product: AURN001 + Y-27632
- Where
- 12 sites in United States
- Volunteers
- 130 people
- Sponsor
- Aurion Biotech
Presbyopia
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when…
- Trial name
- GEMINI 2 (NCT03857542)
- Testing
- Pilocarpine HCl Ophthalmic Solution, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 427 people
- Sponsor
- Allergan
Dry Eye Disease
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT04268069
- Testing
- PL9643 Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- ORA, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.